- Home
- MBOT vs HURA Comparison
MBOT vs HURA Comparison
Compare MBOT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBOT | HURA |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 144.3M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBOT | HURA |
|---|---|---|
| Price | $1.73 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.50 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.6M | 557.7K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,887.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.41 |
| 52 Week High | $4.62 | $3.90 |
Technical Indicators
Market Signals| Indicator | MBOT | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 50.52 |
| Support Level | $1.65 | $2.24 |
| Resistance Level | $2.23 | $2.68 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.85 | 28.95 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.